keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma stage system

keyword
https://www.readbyqxmd.com/read/28647765/epidemiology-of-hepatocellular-carcinoma-target-population-for-surveillance-and-diagnosis
#1
REVIEW
An Tang, Oussama Hallouch, Victoria Chernyak, Aya Kamaya, Claude B Sirlin
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer mortality worldwide. Incidence rates of liver cancer vary widely between geographic regions and are highest in Eastern Asia and sub-Saharan Africa. In the United States, the incidence of HCC has increased since the 1980s. HCC detection at an early stage through surveillance and curative therapy has considerably improved the 5-year survival. Therefore, medical societies advocate systematic screening and surveillance of target populations at particularly high risk for developing HCC to facilitate early-stage detection...
June 24, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28638790/evolving-role-of-sorafenib-in-the-management-of-hepatocellular-carcinoma
#2
REVIEW
Ioannis A Ziogas, Georgios Tsoulfas
Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality. Although there is a broad spectrum of treatment options to choose from, only a few patients are eligible candidates to receive a curative therapy according to their stage of disease, and thus palliative treatment is implemented in the majority of the patients suffering from liver cancer. Sorafenib, a multikinase inhibitor, is the only currently approved agent for systemic therapy in patients with advanced stage HCC and early stage liver disease...
June 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28638267/synergistic-antitumor-effect-of-sorafenib-in-combination-with-atm-inhibitor-in-hepatocellular-carcinoma-cells
#3
Jianhua Liu, Yahui Liu, Lingyu Meng, Bai Ji, Daqing Yang
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC patients indicate that sorafenib alone has only moderate antitumor efficacy, and could not inhibit disease metastasis and progression. KU-55933 is a specific ATM inhibitor, which has pro-apoptotic effect on tumor cells. In this study, we analyzed the synergistic effect of sorafenib and KU-55933 on the proliferation of HCC cell lines. Methods: Three HCC cell lines were treated with sorafenib and KU-55933 alone or combination in vitro to investigate inhibitory effect by MTT and wound healing assay...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28636293/-treatment-of-advanced-hepatocellular-carcinoma-novel-agents-and-role-of-local-therapy
#4
Louis Parisod, Rafael Duran, Alban Denys, Antonia Digklia
The incidence of hepatocellular carcinoma (HCC) is increasing in Switzerland and its treatment is a challenge. The purpose of this article is to summarize the different therapeutic approaches in the metastatic stage, as well as the perspectives of targeted treatments and immunotherapy. Until recently, the only recognized therapeutic standard for these patients with metastatic CHC was sorafenib, a tyrosine kinase inhibitor. If the patient was to progress under sorafenib, no other recognized therapeutic option was available as second line...
May 17, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28628497/predicting-short-term-and-long-term-mortality-of-hospitalized-portuguese-patients-with-alcoholic-hepatitis
#5
Samuel R Fernandes, Pedro Marques da Costa, Sofia Vítor, Joana R Carvalho, Patrícia Santos, Carlos M Moura, Helena Cortez-Pinto, Fernando Ramalho, José Velosa
BACKGROUND: Alcohol abuse can result in a spectrum of liver injury that ranges from mild fatty infiltration to alcoholic hepatitis (AH), cirrhosis, and hepatocellular carcinoma. The present study aimed to evaluate current scoring systems in predicting short-term and long-term mortality because of AH. PATIENTS AND METHODS: Records of 170 consecutive patients with AH admitted to a tertiary center between January 2005 and October 2015 were reviewed. Clinical and biochemical parameters were retrieved for the assessment of AH scores for the day of admission (D1) and for the seventh day of hospitalization (D7)...
June 16, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28626732/albumin-bilirubin-albi-grade-as-part-of-the-evidence-based-clinical-practice-guideline-for-hcc-of-the-japan-society-of-hepatology-a-comparison-with-the-liver-damage-and-child-pugh-classifications
#6
Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Hideki Kawasaki, Yoichi Hiasa, Kojiro Michitaka
AIM/BACKGROUND: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. METHODS: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group)...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/28618075/surgical-treatment-for-advanced-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#7
REVIEW
Kazuhiko Sakamoto, Hiroaki Nagano
The Barcelona Clinic Liver Cancer (BCLC) staging system recommends administration of a tyrosine kinase inhibitor (sorafenib) as standard therapy in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). Sorafenib has been shown to prolong median overall survival (OS) by about 3 months in advanced HCC patients with PVTT (8.1 vs 4.9 months). However, its clinical effectiveness is still controversial and standard treatment with sorafenib is not established in Japan. Surgical resection is considered as a potentially curative treatment and provides an acceptable outcome for carefully selected patients...
June 15, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28612162/li-rads-and-transplantation-for-hepatocellular-carcinoma
#8
REVIEW
An Tang, Kathryn J Fowler, Victoria Chernyak, William C Chapman, Claude B Sirlin
Patients with hepatocellular carcinoma (HCC) may be eligible for liver transplantation. Liver transplant candidates with HCC compete for the same deceased donor organs as those without HCC. These scarce organs must be allocated fairly and justly to those who will benefit most. Unlike most other cancers, HCC is often diagnosed noninvasively by imaging without biopsy confirmation. Therefore, radiologists play an important role in diagnosing definite HCC (i.e., LR-5 category) that counts toward staging and determination of liver transplant eligibility...
June 13, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28611259/prevalence-risk-factors-and-survival-of-patients-with-intrahepatic-cholangiocarcinoma
#9
Paulina Chinchilla-López, Nancy Aguilar-Olivos, Jaime García-Gómez, Karen Hernández-Alejandro, Fredy Chablé-Montero, Daniel Motola-Kuba, Tushar Patel, Nahum Mendez-Sánchez
PURPOSE: To investigate the prevalence, related risk factors, and survival of intrahepatic cholangiocarcinoma in a Mexican population. MATERIAL AND METHODS: We conducted a cross-sectional study at Medica Sur Hospital in Mexico City with approval of the local research ethics committee. We found cases by reviewing all clinical records of in-patients between October 2005 and January 2016 who had been diagnosed with malignant liver tumors. Clinical characteristics and comorbidities were obtained to evaluate the probable risk factors and the Charlson index...
August 1, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28610406/prognostic-nomogram-for-advanced-hepatocellular-carcinoma-treated-with-folfox-4
#10
Shukui Qin, Xinji Zhang, Wei Guo, Jian Feng, Tianyi Zhang, Lichuang Men, Jia He
Background: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. However, the efficacy of FOLFOX4 for HCC patients is still under debate. In this study, we aimed to establish a nomogram to identify HCC patients who might benefit from FOLFOX4 chemotherapy base on individual profile. Methods: A total of 184 patients from the EACH study who were treated with FOLFOX4 were included in this analysis...
May 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28609841/mir-200c-5p-suppresses-proliferation-and-metastasis-of-human-hepatocellular-carcinoma-hcc-via-suppressing-mad2l1
#11
Yuanhang Li, Weijun Bai, Jianjun Zhang
OBJECTIVE: To explore the biological functions of miR-200c-5p/MAD2L1 axis on the proliferation and metastasis of human hepatocellular carcinoma (HCC) cells. METHODS: The expression levels of miR-200c-5p and MAD2L1 in HCC tissues, adjacent tissues as well as HCC cell lines were detected by RT-qPCR or Western blot. The interaction between miR-200c-5p and MAD2L1 was verified by dual luciferase reporter gene system. Transfection was performed to manipulate the expression of miR-200c-5p and MAD2L1 in HCCLM3 cells...
June 9, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28609160/circulating-scca-igm-complex-is-a-useful-biomarker-to-predict-the-outcome-of-therapy-in-hepatocellular-carcinoma-patients
#12
Maria Guarino, Giovan G Di Costanzo, Andrea Gallotta, Raffaella Tortora, Laura Paneghetti, Francesco Auriemma, Concetta Tuccillo, Giorgio Fassina, Nicola Caporaso, Filomena Morisco
INTRODUCTION: Hepatocellular carcinoma (HCC) develops in about 3-4% of cirrhotic patients every year. The squamous cell carcinoma antigen (SCCA) has been found elevated in liver cancer specimens by immunohistochemistry, and detected in complex with IgM (SCCA-IgM) in the serum of patients with HCC. The aim of this study was to evaluate the ability of serological SCCA-IgM levels to predict the efficacy of HCC therapy. MATERIALS AND METHODS: From April 2012 to April 2014, 131 patients with a new diagnosis of HCC were enrolled...
June 13, 2017: Scandinavian Journal of Clinical and Laboratory Investigation
https://www.readbyqxmd.com/read/28605614/medical-management-of-hepatocellular-carcinoma
#13
Nicole E Rich, Adam C Yopp, Amit G Singal
Hepatocellular carcinoma (HCC) typically occurs in patients with advanced liver disease, so therapeutic decisions must account for the degree of underlying liver dysfunction and patient performance status in addition to tumor burden. Curative treatment options, including liver transplantation, surgical resection, and local ablative therapies, offer 5-year survival rates exceeding 60% but are restricted to patients with early-stage HCC. Surgical resection and local ablative therapies are also limited by high recurrence rates, highlighting a need for adjuvant and/or neoadjuvant therapies...
June 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28596819/usefulness-of-the-mesh-score-in-a-european-hepatocellular-carcinoma-cohort
#14
Xavier Adhoute, Guillaume Pénaranda, Jean-Luc Raoul, Marc Bourlière
The Barcelona Clinic Liver Cancer classification is the most widely - used hepatocellular carcinoma (HCC) staging system because it is simple, precise and linked to a treatment algorithm based on randomized studies. But each group includes a broad spectrum of tumors, with limited therapeutic options, particularly for intermediate and advanced stages. Consequently, different additional scoring systems have been proposed to refine the prognosis and/or to improve the management. But until now, there is no consensus...
May 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28593566/cellular-and-molecular-targets-for-the-immunotherapy-of-hepatocellular-carcinoma
#15
REVIEW
Vikrant Rai, Joe Abdo, Abdullah N Alsuwaidan, Swati Agrawal, Poonam Sharma, Devendra K Agrawal
Liver cancer is the sixth most common cancer worldwide and 3rd most common cause of cancer-related death. Hepatocellular carcinoma (HCC) represents more than 90% of primary liver cancer and is a major public health problem. Due to the advanced stages of HCC at the time of diagnosis, utilizing the conventional treatment for solid tumors frequently ends with treatment failure, recurrence, or poor survival. HCC is highly refractory to chemotherapy and other systemic treatments, and locoregional therapies or selective internal radiation therapies are largely palliative...
June 7, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28591740/prognostic-value-and-preoperative-predictors-of-microvascular-invasion-in-solitary-hepatocellular-carcinoma-%C3%A2-5-cm-without-macrovascular-invasion
#16
Hui Zhao, Ye Hua, Zhihua Lu, Shen Gu, Laifa Zhu, Yuan Ji, Yudong Qiu, Tu Dai, Huihan Jin
OBJECTIVES: The aim of this study was to investigate the prognostic value and preoperative predictors of microvascular invasion (MVI) in solitary hepatocellular carcinoma (HCC) ≤ 5 cm without macrovascular invasion. METHODS: A total of 233 consecutive HCC patients underwent curative hepatectomy were included in our study. Independent risk factors influencing the prognosis were identified, and preoperative predictors for MVI were determined. RESULTS: Multivariate regression analysis identified ICG-R15, BCLC staging and MVI as independent risk factors for the overall survival rate...
May 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28590929/prognostic-nomogram-for-hepatocellular-carcinoma-in-adolescent-and-young-adult-patients-after-hepatectomy
#17
Wei Zhang, Yifei Tan, Shu Shen, Li Jiang, Lunan Yan, Jiayin Yang, Bo Li, Tianfu Wen, Yong Zeng, Wen Tao Wang, Mingqing Xu
BACKGROUND: Hepatocellular carcinoma (HCC) was rarely discussed in adolescent and young adult (AYA) patients. This study aimed to discuss the character of AYA HCC patients and establish an effective prognostic nomogram for patients after hepatectomy. RESULTS: For all of the patients, the median OS was 57 months with 5-year OS rate 60.4%, and DFS was 48 months with 5-year DFS rate 51.4%. The tumor size, vascular invasion status and the pathological differentiation were the independent predictors for both OS and DFS...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28586195/ex-vivo-cell-based-screening-platform-for-modulators-of-hepatosteatosis
#18
Shan Yu, Emily Chen, Lance Sherwood, Mitchell Hull, Ashley K Woods, Matthew S Tremblay
Nonalcoholic fatty liver disease (NAFLD) is the result of the ectopic accumulation of lipids in hepatic cells and is the early stage of liver diseases including fibrosis, cirrhosis, and hepatocellular carcinoma. While some mechanisms of aberrant lipid storage are understood, unbiased phenotypic drug screening holds the potential to identify new therapeutic small molecule mechanisms that reverse lipid accumulation in hepatic cells and prevent disease progression. Immortalized hepatocyte cell lines are often used as in vitro models of hepatocyte function, including in the study of lipid accumulation...
June 16, 2017: ACS Chemical Biology
https://www.readbyqxmd.com/read/28581250/new-intermediate-stage-subclassification-for-patients-with-hepatocellular-carcinoma-treated-with-transarterial-chemoembolization
#19
Jin Hyoung Kim, Ju Hyun Shim, Han Chu Lee, Kyu-Bo Sung, Heung-Kyu Ko, Gi-Young Ko, Dong Il Gwon, Jong Woo Kim, Young-Suk Lim, Seong Ho Park
AIM: The need for a subclassification of Barcelona Clinic Liver Cancer (BCLC) intermediate-stage (BCLC B) has arisen because of its diversity. We evaluated the prognostic capability of the BCLC B subclassification proposed by Bolondi et al. in patients treated with transarterial chemoembolization (TACE). Furthermore, we introduce a new subclassification for intermediate-stage hepatocellular carcinoma (HCC) by using a new parameter related to tumor burden (up-to-11 criteria). METHODS: Of 3268 patients treated with TACE as first-line treatment, 821 patients with intermediate-stage HCC were included in this study...
June 5, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28579689/overview-of-staging-systems-for-hepatocellular-carcinoma-and-implications-for-interventional-radiology
#20
REVIEW
Jan Hansmann, Charles E Ray
No abstract text is available yet for this article.
June 2017: Seminars in Interventional Radiology
keyword
keyword
66281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"